Expert Discusses Continued Growth of Immunotherapy in Gastric/GEJ Cancer – OncLive
OncLive |
Expert Discusses Continued Growth of Immunotherapy in Gastric/GEJ Cancer
OncLive “Immunotherapy, in terms of biomarker-unselected populations, is probably the most promising [treatment] that we have identified in gastric/GEJ cancer,” said Harry H. Yoon, MD, co-chair, Esophageal/Gastric Cancer Disease Group, at Mayo Clinic. |
